FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer

Media partner

PHARMA · ONCOLOGY · SEPTEMBER 9, 2026 · UNITED STATES

Decades of failed drug development in pancreatic cancer ended, at least partially, on August 27, 2026, when the FDA cleared daraxonrasib — sold under the brand name Rasonque and developed by Revolution Medicines, a California-based biotechnology company — for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment or cannot access combination regimens. The agency completed its review 6.5 months ahead of its target date, according to the FDA’s own announcement.

The clinical data underpinning the decision are unusually clear-cut for a disease that has resisted therapeutic progress for generations. A randomized, multicenter, open-label phase III trial enrolling 500 previously treated adults showed a median overall survival (OS) of 13.2 months in the daraxonrasib arm, compared with 6.7 months in the standard chemotherapy arm, per trial results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and simultaneously published in The New England Journal of Medicine. The trial also reported a 60% reduction in the risk of death, according to Infobae’s reporting on the ASCO presentation. The absolute survival rates at defined time points were not disclosed in the available record.

The mechanism is specific and, by oncology standards, broad. Daraxonrasib acts as a pan-RAS inhibitor, blocking multiple active variants of the RAS protein family — including G12, G13, and Q61 subtypes — rather than targeting a single point mutation. KRAS, the most commonly altered member of that family, is mutated in more than 90% of pancreatic tumors, according to Infobae citing the trial investigators. Earlier RAS-directed compounds were designed against individual mutations; daraxonrasib’s multi-variant coverage is what distinguishes it mechanistically from prior attempts. The drug is administered orally once daily.

The five-year survival rate for stage 4 pancreatic cancer stands at 3%, according to the World Health Organization, as cited by Infobae. Half of patients diagnosed with the metastatic form die within three months. Against that baseline, a near-doubling of median OS in a 500-patient randomized trial represents a clinically material shift in what the disease’s treatment landscape can offer — though the trial design was open-label, a structural limitation that can introduce performance bias in patient-reported and investigator-assessed endpoints. The FDA’s decision to grant approval on this data, and to do so ahead of schedule, indicates the agency judged the benefit-risk profile sufficient without waiting for longer-term follow-up.

The accelerated timeline is itself informative. According to Infobae’s November 2025 reporting, the FDA granted Revolution Medicines a novel expedited review designation under the Commissioner’s National Priority Valley initiative, a program designed to compress review timelines for promising therapies. The FDA has stated the program can shorten a review from roughly one year to as little as one month. The pancreatic cancer approval appears to be among the first high-profile tests of that mechanism at the approval stage.

The principal friction point for patients and payers is not regulatory — it is access. Daraxonrasib’s list price has not been publicly disclosed, and the available record does not specify reimbursement terms, formulary placement timelines, or coverage decisions by major payers. For a drug targeting a population that, by definition, has already exhausted at least one prior line of therapy, the speed of formulary inclusion by commercial insurers and government programs will determine how quickly the survival benefit observed in the trial translates to real-world patients. That process operates on its own calendar, independent of the FDA’s.

The broader pipeline signal may be as consequential as the approval itself. According to academic researchers cited by Infobae, at least 79 drugs using a RAS-targeting strategy are currently under evaluation across 238 clinical trials in multiple countries. One week after the pancreatic approval, a phase 1-2 trial of 136 patients with advanced or metastatic lung cancer — published in The New England Journal of Medicine — reported tumor reductions in more than 30% of participants treated with daraxonrasib, according to Infobae’s September 3, 2026 reporting. Lung cancer data from a phase 1-2 study are hypothesis-generating, not a demonstrated regulatory-grade effect; the trial was not designed to support an approval claim. But the result, arriving days after the pancreatic clearance, reinforces the mechanistic case that pan-RAS inhibition may be active across tumor types driven by RAS-pathway alterations — a population that includes a substantial share of lung and colorectal cancers, which together with pancreatic cancer represent the leading causes of cancer mortality.

Angelo de Claro, director of the FDA’s Oncology Center of Excellence, stated that daraxonrasib showed results in an area of high unmet medical need, according to the agency’s announcement as reported by Infobae. Kyle Diamantas, the agency’s acting commissioner, described the approval as adding an alternative for patients facing a difficult-to-treat cancer. Neither statement addressed pricing, reimbursement, or the conditions under which the drug would be available outside the United States.

The deeper structural point is one of sequencing risk. Daraxonrasib’s approval was built on a trial in previously treated patients — a population with no remaining standard options, where a survival benefit is easier to demonstrate. Whether the drug performs as well in earlier lines of therapy, or in combination with existing regimens, remains an open clinical question. The approval opens the market; it does not define the drug’s ultimate position within it.

‘